On ECHEMI
Home > Drugs > Hebei Changtian Pharmaceutical Co., Ltd.
Hebei Changtian Pharmaceutical Co., Ltd.
  • Founded in:

    1990-02-27
  • Country:

    China China
  • Address:

    No. 493 Dongfeng East Road, Baoding City
  • Tax NO.:

    911306001059456173
  • Registered Funds:

    30 million yuan
  • Website:

  • Email:

Related Drugs
Aniracetam Granules
1-p-Anisyl-2-pyrrolidone
Name Description Content CAS NO. Registered Holders
1-p-anilino-2-pyrrolidone

This product selectively acts on the central nervous system through the blood-brain barrier. Animal experiments have shown that this product has a good promoting effect on the memory reproduction process of normal rats' discrimination learning, and can fight against memory loss caused by hypoxia. It can effectively improve memory disorders caused by certain reasons.

More

This product selectively acts on the central nervous system through the blood-brain barrier. Animal experiments have shown that this product has a good promoting effect on the memory reproduction process of normal rats' discrimination learning, and can fight against memory loss caused by hypoxia. It can effectively improve memory disorders caused by certain reasons.

0
Simvastatin Capsules
The main ingredient of this product is simvastatin.
Name Description Content CAS NO. Registered Holders
Simvastatin

This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease.

More

This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease.

79902-63-9 63
Dexamethasone Sodium Phosphate Injection
Dexamethasone sodium phosphate. Its chemical name is: 16α-methyl-11β,17α,21-trihydroxy-9α-fluoropregnane-1,4-diene-3,20-dione-21-phosphate disodium salt.
Name Description Content CAS NO. Registered Holders
Dexamethasone sodium phosphate

Adrenal cortex hormone drugs. It has anti-inflammatory, anti-allergic, anti-rheumatic and immunosuppressive effects. Its mechanism of action is: 1. Anti-inflammatory effect: This product reduces and prevents the tissue's response to inflammation, thereby reducing the manifestations of inflammation. It can inhibit the accumulation of inflammatory cells, including macrophages and leukocytes, at the site of inflammation, and inhibit phagocytosis, the release of lysosomal enzymes, and the synthesis and release of inflammatory chemical mediators. 2. Immunosuppressive effect: including preventing or inhibiting cell-mediated immune responses, delayed allergic reactions, reducing the number of T lymphocytes, monocytes, and eosinophils, reducing the ability of immunoglobulins to bind to cell surface receptors, and inhibiting the synthesis and release of interleukins, thereby reducing the transformation of T lymphocytes into lymphoblasts.

More

Adrenal cortex hormone drugs. It has anti-inflammatory, anti-allergic, anti-rheumatic and immunosuppressive effects. Its mechanism of action is: 1. Anti-inflammatory effect: This product reduces and prevents the tissue's response to inflammation, thereby reducing the manifestations of inflammation. It can inhibit the accumulation of inflammatory cells, including macrophages and leukocytes, at the site of inflammation, and inhibit phagocytosis, the release of lysosomal enzymes, and the synthesis and release of inflammatory chemical mediators. 2. Immunosuppressive effect: including preventing or inhibiting cell-mediated immune responses, delayed allergic reactions, reducing the number of T lymphocytes, monocytes, and eosinophils, reducing the ability of immunoglobulins to bind to cell surface receptors, and inhibiting the synthesis and release of interleukins, thereby reducing the transformation of T lymphocytes into lymphoblasts.

55203-24-2 24
Xuesetong Injection
Total saponins of Panax notoginseng.
Name Description Content CAS NO. Registered Holders
Panax notoginsenosides

It has anti-cerebral ischemia effect, improves brain edema in rats with multiple cerebral infarction, promotes glial cell reaction of brain softening foci, accelerates the absorption and organization of softening foci, and alleviates neuronal lesions in the hippocampus; it has a protective effect on delayed neuronal damage in the hippocampus of gerbils with transient cerebral ischemia, reduces the Ca2+ content in brain tissue after ischemia, reduces the number of dead neurons, and increases neuronal density. It has anti-myocardial ischemia effect, reduces the downward shift of the S-T segment of the electrocardiogram in rats with acute myocardial ischemia, and adjusts the heterogeneity of the electrocardiogram. It improves blood rheology, reduces whole blood viscosity, plasma viscosity, hematocrit, platelet aggregation rate, slows down the erythrocyte sedimentation rate, and reduces fibrinogen content. It improves microcirculation, reduces the morphological integral, flow integral, semi-circular integral, and overall integral of the nail fold microcirculation, reduces peri-loop exudation, reduces the tube diameter, increases the flow rate, reduces red blood cell aggregation, reduces the congestion of the top of the loop, increases the clarity of the tube loop, and subsides edema. It has the effect of lowering blood lipids, reducing total cholesterol, triglycerides, and low-density lipoprotein levels. It has the effect of resisting free radical damage, increasing the activity of superoxide dismutase in erythrocytes, reducing the content of plasma malondialdehyde, and reducing the content of serum protein kinase C and aspartate aminotransferase.

More

It has anti-cerebral ischemia effect, improves brain edema in rats with multiple cerebral infarction, promotes glial cell reaction of brain softening foci, accelerates the absorption and organization of softening foci, and alleviates neuronal lesions in the hippocampus; it has a protective effect on delayed neuronal damage in the hippocampus of gerbils with transient cerebral ischemia, reduces the Ca2+ content in brain tissue after ischemia, reduces the number of dead neurons, and increases neuronal density. It has anti-myocardial ischemia effect, reduces the downward shift of the S-T segment of the electrocardiogram in rats with acute myocardial ischemia, and adjusts the heterogeneity of the electrocardiogram. It improves blood rheology, reduces whole blood viscosity, plasma viscosity, hematocrit, platelet aggregation rate, slows down the erythrocyte sedimentation rate, and reduces fibrinogen content. It improves microcirculation, reduces the morphological integral, flow integral, semi-circular integral, and overall integral of the nail fold microcirculation, reduces peri-loop exudation, reduces the tube diameter, increases the flow rate, reduces red blood cell aggregation, reduces the congestion of the top of the loop, increases the clarity of the tube loop, and subsides edema. It has the effect of lowering blood lipids, reducing total cholesterol, triglycerides, and low-density lipoprotein levels. It has the effect of resisting free radical damage, increasing the activity of superoxide dismutase in erythrocytes, reducing the content of plasma malondialdehyde, and reducing the content of serum protein kinase C and aspartate aminotransferase.

0
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.